Search

In this article the author discusses the issue concerning the globalization of United States Pharmacopeia (USP). He notes that the organization's investments have been focused on the advancement of its laboratories in Maryland, India, China, and Brazil that are all supporting USP's standards-setting body. Moreover, the author mentions that USP is working with the U.S. Food and Drug Administration (FDA) to update the needed standards for public monographs.